Table of Contents

• Trial overview
• Who was studied
• What was tested
• Trial phase and design
• Outcomes and endpoints
• Patient-focused terms

Trial overview

The provided trial record is a Phase 1/2 interventional study that was completed and enrolled 23 participants.^[1] It studied patients with retinitis pigmentosa linked to mutations in the PDE6B gene and a defect in PDE6ß expression.^[1] The brief aim was to assess the safety of a unilateral subretinal administration of HORA-PDE6B.^[1]

Who was studied

The target population was very specific: patients with retinitis pigmentosa who carried PDE6B gene mutations.^[1] This means the trial was not for all people with eye disease, but for a smaller group with a known genetic cause.^[1] In simple words, the study focused on people whose vision problem was linked to a particular inherited gene change.^[1]

The trial was also limited to treatment in one eye only, which is what unilateral means.^[1] This kind of design can help researchers compare safety in the treated eye with the untreated eye when needed.^[1]

What was tested

The main study treatment described in the record was a subretinal administration of HORA-PDE6B, which means the treatment was placed under the retina.^[1] The trial title also lists several eye medicines and supportive treatments, including atropine, CHIBRO CADRON, INDOCOLLYRE 0,1 %, MYDRIASERT, and dexamethasone, as part of the study procedures.^[1] The source data does not say these were the main research question; the main goal remained safety of the subretinal study treatment.^[1]

Trial phase and design

This was an interventional trial, which means the research team gave a treatment and then observed the results.^[1] The study phase was Phase 1/2, an early stage that usually looks first at safety and then at early signs that a treatment may help.^[1] Because it was completed, the study has already finished collecting its planned data.^[1]

Outcomes and endpoints

The primary outcome was safety, measured through routine ophthalmic examination, intraocular inflammation, chorioretinal tolerance, questionnaire results, vital signs, and laboratory measurements.^[1] These are standard ways to check whether the eye and the rest of the body handled the treatment well.^[1] In patient terms, the study looked for signs of eye irritation, changes in the back of the eye, and any general health changes during the trial.^[1]

The record also mentions safety and efficacy in the title, but the only endpoint described in the source data is the safety-focused primary endpoint.^[1] Because of that, the clearest trial message is that this study was mainly designed to see if the treatment could be given safely in this patient group.^[1]

Patient-focused terms

Ophthalmic examination means a standard eye check-up used to look at the eye and vision-related structures.^[1] Inflammation means swelling or irritation, and in this study it was checked inside the eye.^[1] Laboratory measurements are blood or other test results that help show whether the body is responding safely to treatment.^[1]

Chorioretinal tolerance refers to how well the back layers of the eye, including the choroid and retina, can handle the treatment.^[1] Questionnaires are forms completed by patients to report symptoms or how they feel during the study.^[1] Together, these measures help researchers build a full picture of safety in a small early-stage trial.^[1]